Keeping cartilagious quality by adalimumab in patient with rheumatoid arthritis in Kansai area

Keeping cartilagious quality by adalimumab in patient with rheumatoid arthritis in Kansai area - KABUKI study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003880

Enrollment

100

Registered

2010-07-07

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

DAS28&gt

3.2 at 24 weeks Switching to another biologics DAS28&gt

3.2 at 24 weeks Dose up of MTX or addition of other DMARDs DAS28&lt

=3.2 at 24 weeks 40 mg of Adalimumab every two week DAS28&lt

=3.2 at 24 weeks 40 mg of Adalimumab every four week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rheumatoid arthritis patients who receive adalimumab under an adaptation of biologics

Exclusion criteria

Exclusion criteria: A malignant tumor, a lymphoma, active tuberculosis, demyelinating disease, congestive heart failure

Design outcomes

Primary

Measure	Time frame
Disease activity score 28 (DAS28), modified Health Assessment Questionnaire (mHAQ), Cartilage Oligometric Matrix Protein (COMP), Sharp score, Echo score	—

Countries

Japan

Contacts

Public ContactTatsuya Koike

Osaka City University Medical School Rheumatosurgery

tatsuya@med.osaka-cu.ac.jp06-6645-3984

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026